Hydroxychloroquine in dermatology: New perspectives on an old drug.

Australas J Dermatol

Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London at Royal Free Hospital London, London, UK.

Published: May 2020

Hydroxychloroquine is an age-old drug whose use as an immunomodulatory agent with a low side-effect profile continues to expand. We present a review of this drug including recently updated prescribing recommendations and a summary of its clinical application in dermatology. A maximum daily dose of 5.0 mg/kg based on actual body weight and no greater than 400 mg is advised in order to reduce the risk of retinopathy, which is potentially permanent and has an estimated prevalence of 7.5% at 5 years on standard dosing. Baseline ophthalmologic assessment followed by annual screening after 5 years is recommended; however, closer monitoring should be considered in the setting of existing retinopathy, a cumulative dose > 1000 g or renal dysfunction. Hydroxychloroquine is now considered to be safe in pregnancy, and routine glucose-6-phosphate dehydrogenase (G6PD) deficiency testing is not required. Smoking can significantly decrease its efficacy although the reason is still uncertain. Hydroxychloroquine appears to also demonstrate antineoplastic and cardioprotective benefits.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajd.13168DOI Listing

Publication Analysis

Top Keywords

hydroxychloroquine
4
hydroxychloroquine dermatology
4
dermatology perspectives
4
perspectives drug
4
drug hydroxychloroquine
4
hydroxychloroquine age-old
4
age-old drug
4
drug immunomodulatory
4
immunomodulatory agent
4
agent low
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!